My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

44.88 +1.08 (+2.47%)

Streaming Delayed Price Updated: 2:42 PM EST, Dec 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Short Volatility Alert: AnaptysBio, Inc. ↗

May 26, 2022

On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment...

Via Benzinga

AnaptysBio's Return On Capital Employed Insights ↗

May 24, 2022

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

Via Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers ↗

April 28, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022 ↗

March 22, 2022

Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Procter & Gamble had an EPS of $1.66,...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗

March 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne ↗

March 15, 2022

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne

Via Benzinga

Recap: AnaptysBio Q4 Earnings ↗

March 07, 2022

AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 14, 2022

Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.

Via Benzinga

AnaptysBio's Return On Capital Employed Insights ↗

March 10, 2022

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of...

Via Benzinga

Hoth Therapeutics Reports Being Set To Begin Phase 2 Study On First-Of-Its-Kind Skin Toxicity Ointment For Cancer Patients ↗

February 01, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children ↗

October 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...

Via Benzinga

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis ↗

October 04, 2021

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and...

Via Benzinga

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication ↗

August 18, 2021

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with...

Via Benzinga

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More ↗

May 08, 2021

Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 ↗

May 21, 2021

Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...

Via Benzinga

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More ↗

May 08, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial...

Via Benzinga

Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More ↗

May 02, 2021

Here are some of the most noteworthy insider purchases that were reported in the past week.

Via Talk Markets

Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More ↗

May 02, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders took advantage of recent public...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.